An observational study in Atrial Fibrillation (AF), sponsored by Eurasian Association of Therapists. Active, not recruiting at 1 site in Russia. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Eurasian Association of Therapists · Observational
Multicenter Non-Interventional Real-World Clinical Practice Registry of Patients with Atrial Fibrillation. The primary objective of the registry is an epidemiological assessment of the characteristics, clinical outcomes, and therapeutic approaches in patients with atrial fibrillation and a CHA₂DS₂-VASc score of no more than 2 for men and no more than 3 for women.
Multicenter Non-Interventional Real-World Clinical Practice Registry of Patients with Atrial Fibrillation. The primary objective of the registry is an epidemiological assessment of the characteristics, clinical outcomes, and therapeutic approaches in patients with atrial fibrillation and a CHA₂DS₂-VASc score of no more than 2 for men and no more than 3 for women.
The registry comprises both a retrospective and a prospective component. Patient enrollment in the retrospective part will be conducted through the review of medical records of individuals who were followed up for atrial fibrillation at the participating centers during the preceding three years. For inclusion in the prospective part, screening of all patients meeting the predefined inclusion and non-inclusion criteria will be performed during routine outpatient and inpatient care, followed by prospective follow-up over a three-year period.
Data derived from the retrospective and prospective phases of the registry will enable an epidemiological assessment of the demographic and clinical characteristics, outcomes, and therapeutic approaches employed in real-world clinical practice among patients with atrial fibrillation. These findings may provide important insights to advance the understanding of diagnostic and management strategies, and to inform efforts aimed at optimizing healthcare delivery within this patient cohort.
3,869 studies on the registry are indexed under Atrial Fibrillation; 923 are open to participants now.
This study's planned enrollment of 3,500 is above the median of 300 across 1,362 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Eurasian Association of Therapists is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Anonymized male and female patients aged 18 to 64 years suffering from atrial fibrillation confirmed by a specialist, with a CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women.
Retrospective Part The retrospective part will include patients who attended a physician consultation for atrial fibrillation three years ago and who met the inclusion criteria at that time.
Inclusion criteria for the retrospective part:
Non-inclusion criteria for the retrospective part:
Prospective Part
Inclusion criteria for the prospective part:
Non-inclusion criteria for the prospective part:
Exclusion criteria:
The retrospective cohort will include patients who attended a physician consultation for atrial fibrillation three years ago and who met the study inclusion criteria at the time of that visit.
All patients aged 18 to 64 years at the time of data registration, with a specialist-confirmed diagnosis of atrial fibrillation and a CHA₂DS₂-VASc score ranging from 0 to 2 for men and from 1 to 3 for women at the time of screening.
Cumulative incidence of thromboembolic complications
To assess the cumulative incidence of atrial fibrillation-related thromboembolic complications (including transient ischaemic attack, ischaemic stroke, and systemic thromboembolism) in patients with initially low risk over the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 month
Number of Atrial Fibrillation Paroxysms During the Follow-up Period
To assess the number of documented episodes (paroxysms) of atrial fibrillation in patients at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 month
Rate of Hospitalizations Due to Atrial Fibrillation Paroxysm During the Follow-up Period
To assess the number of hospitalizations associated with atrial fibrillation paroxysm in patients at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
Rate of Catheter Ablation of Pulmonary Vein Ostia During the Follow-up Period
To assess the number of catheter ablation procedures of the pulmonary vein ostia performed in patients at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
Complications of Anticoagulant Therapy
To assess the incidence of major bleeding (including hemorrhagic stroke), moderate bleeding, and minor bleeding in patients at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Antiplatelet Therapy (Acetylsalicylic Acid, Clopidogrel, Ticagrelor) to Oral Anticoagulants During the Follow-up Period
To assess the proportion of patients who switched from antiplatelet therapy (acetylsalicylic acid, clopidogrel, ticagrelor) to oral anticoagulants at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Oral Anticoagulants to Antiplatelet Therapy (Acetylsalicylic Acid, Clopidogrel, Ticagrelor) During the Follow-up Period
To assess the proportion of patients who switched from oral anticoagulants to antiplatelet therapy (acetylsalicylic acid, clopidogrel, ticagrelor) at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Warfarin to Direct Oral Anticoagulants During the Follow-up Period
To assess the proportion of patients who switched from warfarin to direct oral anticoagulants at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
Proportion of Patients Who Switched from Direct Oral Anticoagulants to Warfarin During the Follow-up Period
To assess the proportion of patients who switched from direct oral anticoagulants to warfarin at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
Hospitalization for Cardiovascular Disease
To assess the rate of hospitalizations related to cardiovascular disease in patients at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
All-Cause Hospitalization
To assess the rate of hospitalizations for any cause in patients at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
All-Cause Mortality
To assess the rate of death from any cause in patients at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
Cardiovascular Mortality
To assess the rate of death from cardiovascular causes in patients at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
Death from Hemorrhagic Complications, Including Hemorrhagic Stroke
To assess the rate of death related to hemorrhagic complications (including hemorrhagic stroke) in patients at each visit throughout the follow-up period.
Time frame: 6, 12, 18, 24, 30, 36 months
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eurasian Association of Therapists